Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Consolidated Net Income (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Consolidated Net Income for 15 consecutive years, with $62000.0 as the latest value for Q2 2025.

  • Quarterly Consolidated Net Income rose 105.0% to $62000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $116000.0 through Dec 2025, up 108.7% year-over-year, with the annual reading at $620000.0 for FY2025, 118.65% up from the prior year.
  • Consolidated Net Income for Q2 2025 was $62000.0 at Aytu Biopharma, up from $54000.0 in the prior quarter.
  • The five-year high for Consolidated Net Income was $381000.0 in Q3 2024, with the low at -$53.3 million in Q1 2022.
  • Average Consolidated Net Income over 5 years is -$8.7 million, with a median of -$1.2 million recorded in 2024.
  • The sharpest move saw Consolidated Net Income plummeted 546.8% in 2021, then soared 158.89% in 2024.
  • Over 5 years, Consolidated Net Income stood at -$11.5 million in 2021, then surged by 42.04% to -$6.7 million in 2022, then soared by 87.46% to -$839000.0 in 2023, then skyrocketed by 114.66% to $123000.0 in 2024, then tumbled by 49.59% to $62000.0 in 2025.
  • According to Business Quant data, Consolidated Net Income over the past three periods came in at $62000.0, $54000.0, and $123000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.